Malaria Antibodies
Malaria
Research/Pre-clinicalActive
Key Facts
About new/era/mabs
new/era/mabs is a private, platform-based biotech service provider leveraging its proprietary selmax technology for high-throughput antibody discovery. Its core value proposition is delivering antibody leads four times faster than conventional methods by using immortal antigen-specific cell pools that allow for infinite screening. The company serves research, diagnostic, and therapeutic partners with tailored antibody sets and manufacturing, with notable applications in infectious diseases (e.g., SARS-CoV-2) and neurodegenerative targets. It appears to be in an early-revenue stage, collaborating with academic and industry partners to advance its platform.
View full company profileTherapeutic Areas
Other Malaria Drugs
| Drug | Company | Phase |
|---|---|---|
| Vaxine Malaria Vaccine | Vaxine | Preclinical |
| Malaria Vaccine | VLP Biotech | Pre-clinical |
| Malaria-on-a-Chip Model | Hesperos | Pre-clinical |
| Dendritic Cell Vaccine | MegaNano BioTech | Pre-clinical |
| Malaria | Keltic Pharma Therapeutics | Pre-clinical |
| Antibody Programs (Malaria) | Ibex Biosciences | Pre-clinical |
| Malaria RDTs | Access Bio | Commercial |
| Malaria Nanobody | VicuTec Biologicals | Pre-clinical |